Serum angiopoietin-2 and CRP levels during COPD exacerbations

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 11, Issue 1, 2014, Pages 46-51

  Nikolakopoulou, Sofia ^a   Hillas, Georgios ^a   Perrea, Despina ^b   Tentolouris, Nikolaos ^b   Loukides, Stylianos ^b   Kostikas, Konstantinos ^b   Simoes, Davina ^b   Georgakopoulou, Erasmia ^a   Vogiatzakis, Evaggelos ^a   Veldekis, Dimitrios ^a   Bakakos, Petros ^b  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Angiopoietin 2; Biomarkers; CRP; Exacerbation; Inflammation

Indexed keywords

ANGIOPOIETIN 2; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; C REACTIVE PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; PREDNISOLONE; STEROID; THEOPHYLLINE;

AGED; ANTIBIOTIC THERAPY; ARTERIAL GAS; ARTICLE; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; KINETICS; LABORATORY TEST; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; VENOUS BLOOD;

AGED; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SPIROMETRY;

EID: 84893269771     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2013.829436     Document Type: Article

References (30)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2011. Available at: http://www.goldcopd.org/guidelines- globalstrategy- for-diagnosis-management.html (accessed on 15 March 2012).
2. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004 Aug; 364(9434):613-620.
3. Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and infl ammation. Int J Chron Obstruct Pulmon Dis 2011; 6:413-421.
4. Agusti AG, Noguera A, Sauleda J, et al. Systemic eff ects of chronic obstructive pulmonary disease. Eur Respir J 2003 Feb; 21(2):347-360.
5. Gan WQ, Man SFP, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic infl ammation: a systematic review and a meta-analysis. Thorax 2004 Jul; 59(7):574-580.
6. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and infl ammation. Trends Immunol. 2006 Dec; 27(12):552-558.
7. Jackson JR, Seed MP, Kircher CH, et al. Th e codependence of angiogenesis and chronic infl ammation. FASEB J. 1997 May; 11(6):457-465.
8. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hy perpermeability, and angiogenesis. Am J Pathol 1995 May; 146(5):1029-1039.
9. Zanini A, Chetta A, Imperatori AS, et al. Th e role of the bronchial microvasculature in the airway remodelling in asthma and COPD. Respir Res 2010 Sep; 29(11):132.
10. Walters EH, Soltani A, Reid DW, et al. Vascular remodelling in asthma. Curr Opin Allergy Clin Immunol 2008 Feb; 8(1):39-43.
11. Papaioannou AI, Kostikas K, Kollia P, et al. Clinical implications for vascular endothelial growth factor in the lung: friend or foe? Respir Res 2006 Oct; 17(7):128.
12. Goldie RG, Pedersen KE. Mechanisms of increased airway microvascular permeability: role in airway infl ammation and obstruction. Clin Exp Pharmacol Physiol 1995 Jun-Jul; 22(6- 7): 387-396.
13. Makinde T, Murphy RF, Agrawal DK. Immunomodulatory role of vascular endothelial growth factor and angiopoietin-1 in airway remodeling. Curr Mol Med 2006 Dec; 6(8):831- 841.
14. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 1997 Jul; 277(5322):55-60.
15. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996 Dec; 87(7):1153-1155.
16. Knox AJ, Stocks J, Sutcliff e A. Angiogenesis and vascular endothelial growth factor in COPD. Thorax 2005 Feb; 60(2):88-89.
17. Gale NW, Th urston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev. Cell 2002 Sep; 3(3):411-423.
18. Cho YJ, Ma JE, Yun EY, et al. Serum angiopoietin-2 levels are elevated during acute exacerbations of COPD. Respirology 2011 Feb; 16(2):284-290.
19. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006 Oct; 174(8):867-874.
20. Muller B, Tamm M. Biomarkers in acute exacerbation of chronic obstructive pulmonary disease: among the blind, the one-eyed is king. Am J Respir Crit Care Med 2006 Oct; 174(8):848-849.
21. Patel AR, Hurst JR, Wedzicha JA. Th e potential value of biomarkers in diagnosis and staging of COPD and exacerbations. Semin Respir Crit Care Med 2010 Jun; 31(3):267-275.
22. Antonescu-Turcu AL, Tomic R. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. Curr Opin Pulm Med 2009 Mar; 15(2):120-125.
23. Ruiz-González A, Lacasta D, Ibarz M, et al. C-reactive protein and other predictors of poor outcome in patients hospitalized with exacerbations of chronic obstructive pulmonary disease. Respirology 2008 Nov; 13(7):1028-1033.
24. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002 Oct; 57(10):847-852.
25. Seemungal TAR, Donaldson GC, Paul EA, et al. Eff ect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998 May; 157(5 Pt 1):1418-1422.
26. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005 Nov; 60(11):925-931.
27. Rodriguez-Roisin R. Toward a consensus defi nition for COPD exacerbations. Chest 2000 May; 117(5 Suppl 2):398- 401.
28. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and oTher disease. Nat Med 1995 Jan; 1(1):27-31.
29. Valipour A, Schreder M, Wolzt M, et al. Circulating vascular endothelial growth factor and systemic infl ammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci (Lond) 2008 Oct; 115(7):225-232.
30. Muller B, Peri G, Doni A, et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 2002 Oct; 72(4):643-649.